

Mariano Andr s

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2499958/publications.pdf>

Version: 2024-02-01

142
papers

2,252
citations

304743

22
h-index

254184

43
g-index

148
all docs

148
docs citations

148
times ranked

3339
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. <i>Journal of Infection</i> , 2021, 82, 378-383.	3.3	456
2	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.9	222
3	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 38-45.	3.4	117
4	GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 869-877.	0.9	114
5	Mechanisms of crystal formation in gout—a structural approach. <i>Nature Reviews Rheumatology</i> , 2015, 11, 725-730.	8.0	79
6	Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1531-1539.	5.6	74
7	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019, 71, 427-434.	3.4	73
8	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.9	72
9	Synovial fluid analysis for crystals. <i>Current Opinion in Rheumatology</i> , 2011, 23, 161-169.	4.3	62
10	Hypokalemia as a sensitive biomarker of disease severity and the requirement for invasive mechanical ventilation requirement in COVID-19 pneumonia: A case series of 306 Mediterranean patients. <i>International Journal of Infectious Diseases</i> , 2020, 100, 449-454.	3.3	55
11	Case series of acute arthritis during COVID-19 admission. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e58-e58.	0.9	53
12	Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. <i>Journal of Autoimmunity</i> , 2020, 114, 102523.	6.5	51
13	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268.	0.9	38
14	Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. <i>Rheumatology</i> , 2020, 59, 2544-2549.	1.9	30
15	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , 2016, 55, 1243-1250.	1.9	28
16	Gout: optimizing treatment to achieve a disease cure. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 135-144.	2.5	27
17	Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice. <i>Rheumatology and Therapy</i> , 2018, 5, 243-253.	2.3	25
18	Marked improvement of lung rheumatoid nodules after treatment with tocilizumab. <i>Rheumatology</i> , 2012, 51, 1132-1134.	1.9	24

#	ARTICLE	IF	CITATIONS
19	Methotrexate Is an Option for Patients With Refractory Calcium Pyrophosphate Crystal Arthritis. <i>Journal of Clinical Rheumatology</i> , 2012, 18, 234-236.	0.9	24
20	Lupus nephritis: a 15-year multi-centre experience in the UK. <i>Lupus</i> , 2013, 22, 328-332.	1.6	24
21	Therapy for CPPD: Options and Evidence. <i>Current Rheumatology Reports</i> , 2018, 20, 31.	4.7	24
22	Male pituitary-gonadal axis dysfunction in post-acute COVID-19 syndrome: Prevalence and associated factors: A Mediterranean case series. <i>Clinical Endocrinology</i> , 2022, 96, 353-362.	2.4	24
23	Interleukin-1 inhibitors for acute gout. <i>The Cochrane Library</i> , 2014, 2014, CD009993.	2.8	23
24	Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e131-e131.	0.9	23
25	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. <i>Arthritis Care and Research</i> , 2022, 74, 1649-1658.	3.4	23
26	Gout treatment: should we aim for rapid crystal dissolution?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 635-637.	0.9	22
27	Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout. <i>Rheumatology</i> , 2021, 60, 4855-4860.	1.9	22
28	Clinical Frailty Score vs Hospital Frailty Risk Score for predicting mortality and other adverse outcome in hospitalised patients with COVID-19: Spanish case series. <i>International Journal of Clinical Practice</i> , 2021, 75, e14599.	1.7	21
29	Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. <i>Lupus</i> , 2020, 29, 1556-1565.	1.6	19
30	Dietary supplements for chronic gout. <i>The Cochrane Library</i> , 2014, , CD010156.	2.8	18
31	Severe gout: Strategies and innovations for effective management. <i>Joint Bone Spine</i> , 2017, 84, 541-546.	1.6	18
32	Plasma ACE2 species are differentially altered in COVID-19 patients. <i>FASEB Journal</i> , 2021, 35, e21745.	0.5	18
33	Diagnostic Value of Clinical, Laboratory, and Imaging Findings in Patients with a Clinical Suspicion of Gout: A Systematic Literature Review. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 3-8.	2.2	16
34	An integrated emergency department/hospital at home model in mild COVID-19 pneumonia: feasibility and outcomes after discharge from the emergency department. <i>Internal and Emergency Medicine</i> , 2021, 16, 1673-1682.	2.0	15
35	Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 155-155.	0.9	14
36	The COVID-GRAM Tool for Patients Hospitalized With COVID-19 in Europe. <i>JAMA Internal Medicine</i> , 2021, 181, 1000-1001.	5.1	14

#	ARTICLE	IF	CITATIONS
37	Criteria for Gout Diagnosis?. <i>Journal of Rheumatology</i> , 2013, 40, 356-358.	2.0	12
38	Most needle-shaped calcium pyrophosphate crystals lack birefringence. <i>Rheumatology</i> , 2019, 58, 1095-1098.	1.9	12
39	Fatality and risk features for prognosis in COVID-19 according to the care approach – a retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0248869.	2.5	12
40	Diagnóstico y tratamiento de la gota. <i>Medicina Clínica</i> , 2017, 148, 271-276.	0.6	11
41	Managing Gout in the Patient with Renal Impairment. <i>Drugs and Aging</i> , 2018, 35, 263-273.	2.7	10
42	Sonographic Tophi and Inflammation Are Associated With Carotid Atheroma Plaques in Gout. <i>Frontiers in Medicine</i> , 2021, 8, 795984.	2.6	10
43	Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al. <i>Arthritis and Rheumatology</i> , 2016, 68, 2563-2564.	5.6	9
44	Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report. <i>Joint Bone Spine</i> , 2018, 85, 377-378.	1.6	9
45	Gout Is Prevalent but Under-Registered Among Patients With Cardiovascular Events: A Field Study. <i>Frontiers in Medicine</i> , 2020, 7, 560.	2.6	9
46	Acute arthritis following SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 661-661.	5.0	9
47	Application of validated severity scores for pneumonia caused by SARS-CoV-2. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 99-105.	0.2	9
48	Current advances in therapies for calcium pyrophosphate crystal arthritis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 140-144.	4.3	8
49	Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 53.	3.5	8
50	Persistence of Crystals in Stored Synovial Fluid Samples. <i>Journal of Rheumatology</i> , 2020, 47, 1416-1423.	2.0	8
51	Agreement Among Multiple Observers on Crystal Identification by Synovial Fluid Microscopy. <i>Arthritis Care and Research</i> , 2023, 75, 682-688.	3.4	8
52	Treatment Target and Followup Measures for Patients with Gout: A Systematic Literature Review. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 55-62.	2.2	7
53	Synovial fluid leukocyte count in asymptomatic hyperuricaemia with crystal deposition: a proof-of-concept study. <i>Rheumatology</i> , 2019, 58, 1104-1105.	1.9	7
54	Role of Carotid Ultrasound and Systematic Coronary Risk Evaluation Charts for the Cardiovascular Risk Stratification of Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 682-689.	2.0	7

#	ARTICLE	IF	CITATIONS
55	No hepatitis B reactivation in a patient with refractory antisynthetase syndrome successfully treated with rituximab. <i>Joint Bone Spine</i> , 2011, 78, 653-654.	1.6	6
56	Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease?. <i>Arthritis Research and Therapy</i> , 2015, 17, 89.	3.5	6
57	Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. <i>Reumatología Clínica</i> , 2019, 15, 34-42.	0.5	6
58	Aplicación de escalas pronósticas de gravedad en la neumonía por SARS-CoV-2. <i>Medicina Clínica</i> , 2021, 157, 99-105.	0.6	6
59	Serum Urate Levels of Hemodialyzed Renal Patients Revisited. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e362-e366.	0.9	6
60	Progresses in the imaging of calcium pyrophosphate crystal disease. <i>Current Opinion in Rheumatology</i> , 2020, 32, 140-145.	4.3	5
61	Cribado del virus de papiloma humano: evaluación de grado de vigilancia en artritis reumatoide, artritis psoriásica y lupus eritematoso sistémico. <i>Reumatología Clínica</i> , 2021, 17, 494-498.	0.5	5
62	MRI myositis sine myositis: the importance of the histopathology. <i>Rheumatology</i> , 2015, 54, 76-76.	1.9	4
63	Primoinfección tuberculosa en pacientes con anti-TNF- α y cribado inicial negativo. <i>Reumatología Clínica</i> , 2016, 12, 81-84.	0.5	4
64	Mixed Crystal Disease: A Tale of 2 Crystals. <i>Journal of Rheumatology</i> , 2020, 47, 1158-1159.	2.0	4
65	Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?. <i>Rheumatology</i> , 2021, 60, 5329-5336.	1.9	4
66	Vascular deposition of monosodium urate crystals in gout: analysis of cadaveric tissue by dual-energy computed tomography and compensated polarizing light microscopy. <i>Arthritis and Rheumatology</i> , 2022, 74, 1295-1296.	5.6	4
67	Calcium pyrophosphate crystal deposition. <i>International Journal of Clinical Rheumatology</i> , 2011, 6, 677-688.	0.3	3
68	SAT0328...Uric Acid Enhances Monosodium Urate Induced Pro-Inflammatory Response in Gouty Patients: A Basic and Translational Research Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 777.2-778.	0.9	3
69	Gout: Diagnosis and treatment. <i>Medicina Clínica (English Edition)</i> , 2017, 148, 271-276.	0.2	3
70	Bruton's Tyrosine Kinase Inhibitors Could Induce Rheumatoid Arthritis-Like Manifestations: Comment on the Article by Nyhoff et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 475-475.	5.6	3
71	Is Remission a Valid Target for Gout?. <i>Journal of Rheumatology</i> , 2020, 47, 4-5.	2.0	3
72	Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e124-e124.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Birefringent crystals deposition and inflammasome expression in human atheroma plaques by levels of uricemia. <i>Joint Bone Spine</i> , 2022, 89, 105423.	1.6	3
74	Clinical Images: Osteochondroma leading to Snapping Scapula Syndrome. <i>Arthritis and Rheumatism</i> , 2010, 62, 1838-1838.	6.7	2
75	Small muscle myositis in a patient with systemic lupus erythematosus successfully treated with rituximab. <i>Lupus</i> , 2011, 20, 1340-1341.	1.6	2
76	Lepromatous leprosy presenting as an acute polyarthritis in a Colombian immigrant in Spain. <i>Joint Bone Spine</i> , 2012, 79, 203-204.	1.6	2
77	Back Pain Due to Lumbar Gouty Flare – A Prospective Diagnosis. <i>Journal of Rheumatology</i> , 2013, 40, 1459-1460.	2.0	2
78	Rapid crystal dissolution in gout: is it feasible and advisable?. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 395-401.	0.3	2
79	Pigmented villonodular synovitis diagnostic delay due to coexistence with ankylosing spondylitis. <i>Reumatología Clínica</i> , 2014, 10, 270-271.	0.5	2
80	THU0493 – Association of the Toll-Like Receptor 4 (TLR4) Gene with Gout. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 354.1-354.	0.9	2
81	OP0140-HPR – The Role of a Nurse-Clinic in the Assessment and Prevention of Cardio-Vascular Risk. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 121.3-121.	0.9	2
82	Comment on: The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. <i>Rheumatology</i> , 2015, 54, 1328-1329.	1.9	2
83	Response to: “Comparative analysis of synovial inflammation after SARS-CoV-2 infection” by Alivernini et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e92-e92.	0.9	2
84	Gouty Involvement of Foot and Ankle: Beyond Flares. <i>Reumatología Clínica</i> , 2021, 17, 106-112.	0.5	2
85	Urate levels and clearance in renal patients under peritoneal dialysis. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 720-731.	1.1	2
86	Dealing with refractoriness in obstetric primary antiphospholipid syndrome – often not a matter of success. <i>Lupus</i> , 2014, 23, 964-965.	1.6	1
87	AB0706 – Centre-Related Features Determine Variability of Hospital Admissions of Patients with Spondyloarthritis in Spain: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1037.3-1037.	0.9	1
88	FRI0327 – Febuxostat Appears Effective and Safe in Gout Patients with Severe Chronic Kidney Disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 542.3-543.	0.9	1
89	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: Ascertaining the Efficacy of Treatment Matters. <i>American Journal of Medicine</i> , 2015, 128, e41-e42.	1.5	1
90	THU0494 – Skin Events with Febuxostat in Gout Patients with Previous Skin Reactions To Allopurinol. A Retrospective Review. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 370.3-371.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Gout mimicking rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, e28.	3.4	1
92	Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis. <i>Rheumatology International</i> , 2016, 36, 1515-1523.	3.0	1
93	AB0815â€¦Intraarticular Triamcinolone plus Mepivacaine Provides A Rapid and Sustained Relief for Acute Gouty Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1182.2-1182.	0.9	1
94	Primary Tuberculosis Infection in Patients Treated With Tumor Necrosis Factor-alpha Antagonists and a Negative Initial Screening. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2016, 12, 81-84.	0.3	1
95	Clinical Images: Hematoidin in Synovial Fluid. <i>Arthritis and Rheumatology</i> , 2017, 69, 836-836.	5.6	1
96	Inflammatory status and uricaemia determine HDL-cholesterol levels in hypertensive adults over 65: an analysis of the FAPRES register. <i>Rheumatology International</i> , 2017, 37, 941-948.	3.0	1
97	Gouty arthritis mutilans: obvious but ignored on two occasions. <i>Rheumatology</i> , 2019, 59, 695.	1.9	1
98	SAT0441â€¦SKIN ADVERSE EVENTS WITH FEBUXOSTAT IN GOUT PATIENTSWITH PREVIOUS SKIN REACTIONS TO ALLOPURINOL. A MULTICENTRE DESCRIPTIVE STUDY. , 2019, , .		1
99	Hyperuricemia and the Silent Deposition of Monosodium Urate Crystals. , 2019, , 1-7.		1
100	Riesgo de fracturas vertebrales dorsales osteoporÃticas en pacientes con gota. <i>ReumatologÃa ClÃnica</i> , 2022, 18, 279-285.	0.5	1
101	Gouty Involvement of Foot and Ankle: Beyond Flares. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2021, 17, 106-112.	0.3	1
102	Mediumâ€term serostatus in Spanish case series recovered from SARSâ€CoVâ€2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 6030-6039.	5.0	1
103	Risk of osteoporotic thoracic vertebral fractures in patients with gout. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2021, , .	0.3	1
104	Dietary supplements for chronic gout. <i>The Cochrane Library</i> , 2022, 2022, CD010156.	2.8	1
105	Tratamiento de la enfermedad por cristales de pirofosfato cÃlcico. <i>Seminarios De La FundaciÃ³n EspaÃola De ReumatologÃa</i> , 2010, 11, 159-161.	0.1	0
106	LÃpre lÃpromateuse rÃvÃlant une polyarthrite aiguÃ chez un immigrant colombien rÃsidant en Espagne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012, 79, 178-179.	0.0	0
107	OP0104â€¦Hypouricemia due to high urate renal excretion in septic systemic inflammatory response syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 88.1-88.	0.9	0
108	FRI0325â€¦Silent Deposit of MSU Crystals Associates with a More Severe Coronary Calcification in Asymptomatic Hyperuricemic Patients with Acute Coronary Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 542.1-542.	0.9	0

#	ARTICLE	IF	CITATIONS
109	FRI0104â€¦Ultrasonographic Synovitis in Patients with Rheumatoid Arthritis and Optimization of Subcutaneous Biologic Drugs. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 457.1-457.	0.9	0
110	AB1139â€¦Centre Characteristics Determine Ambulatory Care and Referrals in Patients with Spondyloarthritis:. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1283.1-1283.	0.9	0
111	AB1208â€¦Educational Needs for Young Rheumatologists in Spain. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1307.2-1307.	0.9	0
112	AB0924â€¦Echocardiography Findings in Asymptomatic Hyperuricemic Patients with Silent Deposit of MSU Crystals:. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1209.2-1209.	0.9	0
113	SAT0311â€¦The Shape of Calcium Pyrophosphate Crystals Determines their Intensity of Birefringence. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 770.3-771.	0.9	0
114	Gout and the heart: beyond comorbidities. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 329-334.	0.3	0
115	AB0362â€¦Serum Lipid Level Changes Associated with Tocilizumab Treatment: Our Experience in Two University Hospitals:. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1027.2-1027.	0.9	0
116	SAT0628-HPRâ€¦Cardiovascular Risk Assessment in Inflammatory Arthritis Patients in A Nurse-led Clinic and Supported by Ultrasonography. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1291.1-1291.	0.9	0
117	Centre-related variability in hospital admissions of patients with spondyloarthritis. <i>Rheumatology International</i> , 2016, 36, 1301-1308.	3.0	0
118	THU0508â€¦Improvement in Treat To Target Serum Urate Levels: Results from A Comparison between The Gema and The Gema-II Audits: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 376.1-376.	0.9	0
119	THU0518â€¦New Cardiovascular Risk Factors Screening in Patients with Gout. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 379.2-379.	0.9	0
120	THU0517â€¦Women with Gout Show A Poorer Cardiovascular Profile after Structured Assessment. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 379.1-379.	0.9	0
121	FRI0022â€¦Inflammatory Status and Serum Uric Acid Levels Determine High-Density Lipoproteinâ€œCholesterol Levels in A Non-Rheumatic Population: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 433.2-433.	0.9	0
122	AB0890â€¦Systemic lupus erythematosus and gout: really an unusual association?. , 2017, , .		0
123	THU0441â€¦Synovial fluid leukocyte count and its association with crystal deposition in asymptomatic hyperuricemia: a preliminary report. , 2017, , .		0
124	FRI0571â€¦Osteoporosis and breast cancer: can frax-based risk factors accurately predict further fractures at this setting?. , 2017, , .		0
125	THU0406â€¦Serum uric acid lowering treatment appears unnecessary during hemodialysis. , 2017, , .		0
126	THU0437â€¦Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
127	THU0464â€...A genome-wide association study of gout in people of european ancestry. , 2017, , .		0
128	FRI0570â€...Osteoporosis and breast cancer: outcomes at a specialized osteoporosis clinic following a structured assessment. , 2017, , .		0
129	Urate crystals and inflammation. Cardiovascular impact of gout. International Journal of Cardiology, 2018, 271, 295.	1.7	0
130	OPO249â€...ANTIPHOSPHOLIPID SYNDROME (APS) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) LEADS TO A MORE SEVERE DISEASE. , 2019, , .		0
131	SAT0386â€...PREVALENCE OF SUBCLINICAL CARDIOVASCULAR DISEASE IN PSORIATIC ARTHRITIS: A MULTICENTRIC STUDY. , 2019, , .		0
132	SAT0199â€...POLYAUTOIMMUNITY IN SYSTEMIC LUPUS ERYTHEMATOSUS. DATA FROM A LARGE SPANISH COHORT: SPANISH SOCIETY OF RHEUMATOLOGY REGISTRY OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (RELESSER).. , 2019, , .		0
133	AB0865â€...GOUT IN HOSPITALISED PATIENTS FOR CARDIOVASCULAR DISEASES: PREVALENCE AND MANAGEMENT STATUS. , 2019, , .		0
134	AB0473â€...HYPOGAMMAGLOBULINEMIA AND INFECTIONS IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB. , 2019, , .		0
135	SAT0442â€...CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS DURING HOSPITALIZATIONS: A PROSPECTIVE, CRYSTAL-PROVEN CASE SERIES. , 2019, , .		0
136	SP0062â€...CARDIOVASCULAR MORBIDITY AND GOUT â€“ FROM EPIDEMIOLOGY TO THERAPY. , 2019, , .		0
137	FRI0692â€...34. REHABILITATION HUMAN PAPILLOMA VIRUSSCREENING AND CHRONIC INFLAMMATORY ARTHRITIS: AN AUDIT. , 2019, , .		0
138	Gout Management as Part of Secondary Cardiovascular Prevention: Comment on the Article by Stamp et al. Arthritis and Rheumatology, 2020, 72, 377-377.	5.6	0
139	Gout. Journal of Clinical Rheumatology, 2020, 26, 208-212.	0.9	0
140	Human papilloma virus screening: evaluation of testing and surveillance in rheumatoid arthritis, psoriatic arthritis and systemic lupus erythematosus. ReumatologÃa ClÃnica (English Edition), 2021, 17, 494-498.	0.3	0
141	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. ReumatologÃa ClÃnica, 2022, 18, 129-130.	0.5	0
142	A small dose of intraarticular triamcinolone plus mepivacaine provides a rapid and sustained relief for gout flares. ReumatologÃa ClÃnica (English Edition), 2022, 18, 129-130.	0.3	0